Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation

Yunda Huang; Oleg Borisov; Jia Jin Kee; Lindsay N. Carpp; Terri Wrin; Suqin Cai; Marcella Sarzotti-Kelsoe; Charlene McDanal; Amanda Eaton; Rolando Pajon; John Hural; Christine M. Posavad; Katherine Gill; Shelly Karuna; Lawrence Corey; M. Juliana McElrath; Peter B. Gilbert; Christos J. Petropoulos; David C. Montefiori.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21263049

Documentos relacionados

  1. Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation.
  2. Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation.
  3. Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation.
  4. Immune escape of BA.2.86 is comparable to XBB subvariants from the plasma of BA.5- and BA.5-XBB-convalescent subpopulations.
  5. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
  6. Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout.
  7. Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study.
  8. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern.
  9. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
  10. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.